These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 24220311)

  • 1. Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing.
    De Mattos-Arruda L; Bidard FC; Won HH; Cortes J; Ng CK; Peg V; Nuciforo P; Jungbluth AA; Weigelt B; Berger MF; Seoane J; Reis-Filho JS
    Mol Oncol; 2014 Feb; 8(1):150-8. PubMed ID: 24220311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers.
    Natrajan R; Mackay A; Lambros MB; Weigelt B; Wilkerson PM; Manie E; Grigoriadis A; A'Hern R; van der Groep P; Kozarewa I; Popova T; Mariani O; Turaljic S; Furney SJ; Marais R; Rodruigues DN; Flora AC; Wai P; Pawar V; McDade S; Carroll J; Stoppa-Lyonnet D; Green AR; Ellis IO; Swanton C; van Diest P; Delattre O; Lord CJ; Foulkes WD; Vincent-Salomon A; Ashworth A; Stern MH; Reis-Filho JS
    J Pathol; 2012 May; 227(1):29-41. PubMed ID: 22362584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic.
    Winter C; Nilsson MP; Olsson E; George AM; Chen Y; Kvist A; Törngren T; Vallon-Christersson J; Hegardt C; Häkkinen J; Jönsson G; Grabau D; Malmberg M; Kristoffersson U; Rehn M; Gruvberger-Saal SK; Larsson C; Borg Å; Loman N; Saal LH
    Ann Oncol; 2016 Aug; 27(8):1532-8. PubMed ID: 27194814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases.
    Ng CKY; Bidard FC; Piscuoglio S; Geyer FC; Lim RS; de Bruijn I; Shen R; Pareja F; Berman SH; Wang L; Pierga JY; Vincent-Salomon A; Viale A; Norton L; Sigal B; Weigelt B; Cottu P; Reis-Filho JS
    Clin Cancer Res; 2017 Aug; 23(15):4402-4415. PubMed ID: 28351929
    [No Abstract]   [Full Text] [Related]  

  • 5. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.
    De Mattos-Arruda L; Weigelt B; Cortes J; Won HH; Ng CKY; Nuciforo P; Bidard FC; Aura C; Saura C; Peg V; Piscuoglio S; Oliveira M; Smolders Y; Patel P; Norton L; Tabernero J; Berger MF; Seoane J; Reis-Filho JS
    Ann Oncol; 2014 Sep; 25(9):1729-1735. PubMed ID: 25009010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diverse
    Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
    Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
    [No Abstract]   [Full Text] [Related]  

  • 7. A Novel Germline Mutation of BRCA1 and Integrated Analysis With Somatic Mutation in a Chinese Multi-Cancer Family.
    Yang X; Shang L; Yang L; Sun L; Tuo X; Ma S; Zhao L; Li X; Yang W
    Oncologist; 2024 Jun; 29(6):e837-e842. PubMed ID: 38159086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular determination of the clonal relationships between multiple tumors in BRCA1/2-associated breast and/or ovarian cancer patients is clinically relevant.
    Geurts-Giele WR; van Verschuer VM; van Deurzen CH; van Diest PJ; Pedrosa RM; Collée JM; Koppert LB; Seynaeve C; Dinjens WN
    Mod Pathol; 2017 Jan; 30(1):15-25. PubMed ID: 27612322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
    Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
    Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive analysis of serum tumor markers and BRCA1/2 germline mutations in Chinese ovarian cancer patients.
    Deng H; Chen M; Guo X; Heng J; Xu X; Peng L; Jiang H; Li G; Day JX; Li J; Shan D; Li Y; Zhou Y; Liu B; Dai L; Wang X; Wang J
    Mol Genet Genomic Med; 2019 Jun; 7(6):e672. PubMed ID: 30972954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonal relationship and directionality of progression of synchronous endometrial and ovarian carcinomas in patients with DNA mismatch repair-deficiency associated syndromes.
    Moukarzel LA; Da Cruz Paula A; Ferrando L; Hoang T; Sebastiao APM; Pareja F; Park KJ; Jungbluth AA; Capella G; Pineda M; Levin JD; Abu-Rustum NR; Ellenson LH; Bel AV; Reis-Filho JS; Matias-Guiu X; Cadoo K; Stadler ZK; Weigelt B
    Mod Pathol; 2021 May; 34(5):994-1007. PubMed ID: 33328602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
    Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-risk human papilloma virus infection, tumor pathophenotypes, and BRCA1/2 and TP53 status in juvenile breast cancer.
    Aceto GM; Solano AR; Neuman MI; Veschi S; Morgano A; Malatesta S; Chacon RD; Pupareli C; Lombardi M; Battista P; Marchetti A; Mariani-Costantini R; Podestà EJ
    Breast Cancer Res Treat; 2010 Aug; 122(3):671-83. PubMed ID: 19851859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer.
    Chao A; Chang TC; Lapke N; Jung SM; Chi P; Chen CH; Yang LY; Lin CT; Huang HJ; Chou HH; Liou JD; Chen SJ; Wang TH; Lai CH
    Oncotarget; 2016 Dec; 7(51):85529-85541. PubMed ID: 27907908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
    Škapa P; Dundr P
    Cesk Patol; 2016; 52(4):199-204. PubMed ID: 27869446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
    Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
    Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation analysis of BRCA1, TP53, and KRAS2 in ovarian and related pelvic tumors.
    Tworek H; Peng R; Fetzer S; Werness BA; Piver MS; Allen HJ; DiCioccio RA
    Cancer Genet Cytogenet; 1999 Jul; 112(2):105-18. PubMed ID: 10686936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
    Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
    Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of somatic BRCA1/2 mutations in ovarian cancer - next-generation sequencing analysis of 100 cases.
    Koczkowska M; Zuk M; Gorczynski A; Ratajska M; Lewandowska M; Biernat W; Limon J; Wasag B
    Cancer Med; 2016 Jul; 5(7):1640-6. PubMed ID: 27167707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Family history and BRCA1/BRCA2 status among Japanese ovarian cancer patients and occult cancer in a BRCA1 mutant case.
    Hirasawa A; Masuda K; Akahane T; Ueki A; Yokota M; Tsuruta T; Nomura H; Kataoka F; Tominaga E; Banno K; Makita K; Susumu N; Sugano K; Kosaki K; Kameyama K; Aoki D
    Jpn J Clin Oncol; 2014 Jan; 44(1):49-56. PubMed ID: 24218521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.